Page 385 - Traité de Chimie Thérapeutique 4 Médicaments en relation avec des systèmes hormonaux
P. 385

346                  MEDICAMENTS HNRHLATION A VEC DES SI STÈMHS HORMONAUX


            ROARK W.H. et al. "Inhibitors of acyl-CoA : Cholestérol acyltransferase ACAT. 2.
              Modification of fatty acid anilide ACAT inhibitors : Bioisosteric replacement of the
              amide bond" (1993) J Med Chem, 36 (11), 1662-1668.
            KUMAZAWAT. et al. “ACAT-inhibitors : synthesis and hypocholestérolémie activity of
              dibenzo[b,e]oxepin-11 -carboxamides" (1993) 206th ACS National Meeting Abstract,
              in Chicago, Illinois. Division of Médicinal Chemistry, American Chemical Society,
              1155,16,h Street, NW, Washington, DC 20036.
            CRESWELL M.W. et al. "Tetrahydroisoquinoline anilides, inhibitors of ACAT" (1993)
              ACS 206th National Meeting Abstract in Chicago, Illinois.
            CHANG G. et al. "Arylamide ACAT inhibitors ; évaluation of SAR of the aromatic
              région leading to the discovery of CP-113, 818" (1993) 206th ACS National Meeting
              Abstract, in Chicago, Illinois.
            WILDE R.G. et al. "ACAT-inhibitors with two heterocyclic substituants" (1993) 206th
              ACS National Meeting Abstract, Chicago, Illinois.
            Inhibiteurs de l'HMG-CoA synthase
            MAYER R.J. "Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A synthase by anti­
              biotic 1233 A and other p-lactones" (1990) Biochem Biophys Res Commun, 169,
              610-616.
            WOVKULICH P.M. et al. "Total synthesis of 1233 A" (1993) J Org Chem, 58, 832-839.
            Inhibiteurs de la squalène synthase
            BILLER A. et al. “The first potent inhibitor of squalene synthase. A profound contribu­
              tion of an ether oxygen to inhibitor-enzyme interaction" (1991) J Am Chem Soc,
              113, 8522-8524.
            BAXTER A. "Squalestatin 1, a potent inhibitor of squalene synthase, which lowers
              sérum cholestérol in vivo" (1992) J Biol Chem, 267 (17), 11705-11708.
            SIDEBOTTOM P.J. "The squalestatins, novel inhibitors of squalene synthase produ-
              ced by a species of Phoma. Il Structure élucidation" (1992) J. Antibiotics, 45 (5),
              648-658.
            VERSAGE R.W. et al. "Inhibition of squalene synthase by famesyl methylenebisphos-
              phonate" (1993) 206lh ACS National Meeting Abstract, Chicago, Illinois.
            LESTER M.G. et al. “Structurally simplified squalestatins : a convenient route to a 6,7-
              unsubstituted dérivative" (1993) Tetrahedron Lett, 34 (27), 4357-4360.
            WATSON N.S. et al. "The squalestatins : potent inhibitors of squalene synthase"
              (1993) 206^ ACS National Meeting Abstract, Chicago, Illinois.
            HENSENS O.D. "The zaragosic acids : structure élucidation of new class of squalene
             synthase inhibitors" (1993) Tetrahedron Lett, 34 (3), 399-402.
           BIFTU T. et al. "Sélective protection and relative importance of the carboxylic acid
             group of zaragosic acid A for squalene synthase inhibition" (1994) J Med Chem, 37
             (3), 421-424.
           Inhibiteurs de la squalène époxydase et de l'oxydosqualène cyclase
           HORIE M. "NB-598 : a potent compétitive inhibitor of squalene epoxydase" (1990)
             J Biol Chem 265, 18075-18077.
           HORIE M. " Hypolipidémie effects of NB-598 in dogs" (1991) Atherosclerosis, 88, 183-
             192 ; Elsevier.
   380   381   382   383   384   385   386   387   388   389   390